NCT02549430View on ClinicalTrials.gov

To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

February 9, 2017

Study Completion Date

February 9, 2017

Conditions
Breast Cancer
Interventions
DRUG

Palbociclib

Palbociclib 125 mg/day orally in an ongoing 3:1 schedule (3 weeks on/1 week off)

DRUG

Anastrozole

Continuation of prior anastrozole 1mg/day orally in a continuous regimen

DRUG

Letrozole

Continuation of prior letrozole 2.5mg/day orally in a continuous regimen

DRUG

Exemestane

Continuation of prior exemestane 25mg/day orally in a continuous regimen

DRUG

Fulvestrant

Continuation of prior fulvestrant 500mg intramuscular injection every 4 weeks in a continuous regimen

Trial Locations (6)

20141

Istituto Europeo Oncologia, Milan

24127

Azienda Ospedaliera Papa Giovanni Xxiii, Bergamo

27100

Fondazione Maugeri, Pavia

33100

A.O.U. S. Maria Della Misericordia Di Udine, Udine

72100

Ospedale Antonio Perrino, Brindisi

80131

A.O.U. Federico Ii Di Napoli, Napoli

All Listed Sponsors
lead

Fondazione Sandro Pitigliani

OTHER

NCT02549430 - To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy | Biotech Hunter | Biotech Hunter